Viatris SG&A Expenses 2010-2025 | VTRS
Viatris annual/quarterly sg&a expenses history and growth rate from 2010 to 2025. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
- Viatris sg&a expenses for the quarter ending March 31, 2025 were $0.948B, a 6.82% decline year-over-year.
- Viatris sg&a expenses for the twelve months ending March 31, 2025 were $4.356B, a 7.49% decline year-over-year.
- Viatris annual sg&a expenses for 2024 were $4.426B, a 4.83% decline from 2023.
- Viatris annual sg&a expenses for 2023 were $4.65B, a 11.27% increase from 2022.
- Viatris annual sg&a expenses for 2022 were $4.179B, a 7.73% decline from 2021.
| Viatris Annual SG&A Expenses (Millions of US $) |
|
|---|---|
| 2024 | $4,426 |
| 2023 | $4,650 |
| 2022 | $4,179 |
| 2021 | $4,529 |
| 2020 | $3,345 |
| 2019 | $2,564 |
| 2018 | $2,441 |
| 2017 | $2,576 |
| 2016 | $2,499 |
| 2015 | $2,181 |
| 2014 | $1,626 |
| 2013 | $1,409 |
| 2012 | $1,392 |
| 2011 | $1,215 |
| 2010 | $1,087 |
| 2009 | $1,050 |
| Viatris Quarterly SG&A Expenses (Millions of US $) |
|
|---|---|
| 2025-03-31 | $948 |
| 2024-12-31 | $1,047 |
| 2024-09-30 | $1,003 |
| 2024-06-30 | $1,358 |
| 2024-03-31 | $1,018 |
| 2023-12-31 | $1,606 |
| 2023-09-30 | $1,054 |
| 2023-06-30 | $1,032 |
| 2023-03-31 | $959 |
| 2022-12-31 | $1,265 |
| 2022-09-30 | $1,017 |
| 2022-06-30 | $981 |
| 2022-03-31 | $915 |
| 2021-12-31 | $1,083 |
| 2021-09-30 | $1,055 |
| 2021-06-30 | $1,205 |
| 2021-03-31 | $1,187 |
| 2020-12-31 | $1,361 |
| 2020-09-30 | $658 |
| 2020-06-30 | $719 |
| 2020-03-31 | $605 |
| 2019-12-31 | $654 |
| 2019-09-30 | $633 |
| 2019-06-30 | $669 |
| 2019-03-31 | $608 |
| 2018-12-31 | $633 |
| 2018-09-30 | $577 |
| 2018-06-30 | $623 |
| 2018-03-31 | $608 |
| 2017-12-31 | $660 |
| 2017-09-30 | $664 |
| 2017-06-30 | $621 |
| 2017-03-31 | $631 |
| 2016-12-31 | $711 |
| 2016-09-30 | $657 |
| 2016-06-30 | $581 |
| 2016-03-31 | $549 |
| 2015-12-31 | $596 |
| 2015-09-30 | $537 |
| 2015-06-30 | $564 |
| 2015-03-31 | $483 |
| 2014-12-31 | $426 |
| 2014-09-30 | $418 |
| 2014-06-30 | $404 |
| 2014-03-31 | $378 |
| 2013-12-31 | $392 |
| 2013-09-30 | $350 |
| 2013-06-30 | $315 |
| 2013-03-31 | $351 |
| 2012-12-31 | $355 |
| 2012-09-30 | $342 |
| 2012-06-30 | $359 |
| 2012-03-31 | $337 |
| 2011-12-31 | $301 |
| 2011-09-30 | $319 |
| 2011-06-30 | $314 |
| 2011-03-31 | $280 |
| 2010-12-31 | $290 |
| 2010-09-30 | $272 |
| 2010-06-30 | $268 |
| 2010-03-31 | $256 |
| 2009-12-31 | $269 |
| 2009-09-30 | $260 |
| 2009-06-30 | $280 |
| 2009-03-31 | $242 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $10.317B | $14.739B |
| Viatris, Inc. is a global healthcare company. Its portfolio comprises more than thousand approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic, complex generic, and biosimilar products. Branded products include EpiPen, Amitiza, Lipitor and Viagra. Biosimilars portfolio include pegfilgrastim, trastuzumab and adalimumab biosimilars. It has obtained approval for the biosimilar of Avastin and Insulin Aspart in Europe. The company reports in following segments: Developed Markets, Greater China, JANZ & Emerging Markets. The Developed Markets segment comprises operations in N. America and Europe. The Greater China segment operates in China, Taiwan and Hong Kong. The JANZ segment will report for operations in Japan, Australia and New Zealand, while the Emerging Markets segment will include operations in Asia, the Middle East, South and Central America, Africa and E. Europe. This segment also includes the company's anti-retroviral franchise. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $135.906B | 25.49 |
| Elevance Health (ELV) | United States | $86.723B | 11.19 |
| CVS Health (CVS) | United States | $81.012B | 10.07 |
| Cencora (COR) | United States | $56.449B | 19.64 |
| DiDi Global (DIDIY) | China | $21.556B | 32.71 |
| Natera (NTRA) | United States | $21.537B | 0.00 |
| BioMerieux (BMXMF) | France | $15.890B | 0.00 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $12.928B | 0.00 |
| Solventum (SOLV) | United States | $12.646B | 13.39 |
| CochLear (CHEOY) | Australia | $11.378B | 0.00 |
| Revvity (RVTY) | United States | $10.658B | 18.34 |
| ICON (ICLR) | Ireland | $10.521B | 9.78 |
| Doximity (DOCS) | United States | $9.784B | 45.30 |
| Avantor (AVTR) | United States | $8.797B | 12.78 |
| HealthEquity (HQY) | United States | $8.702B | 42.81 |
| Medpace Holdings (MEDP) | United States | $8.476B | 22.51 |
| Sonic Healthcare (SKHHY) | Australia | $8.311B | 0.00 |
| Charles River Laboratories (CRL) | United States | $6.662B | 13.05 |
| Amplifon S.p.A (AMFPF) | Italy | $4.966B | 27.18 |
| BrightSpring Health Services (BTSG) | United States | $4.149B | 38.40 |
| Bausch + Lomb (BLCO) | Canada | $4.054B | 23.90 |
| Sotera Health (SHC) | United States | $3.474B | 19.74 |
| Alignment Healthcare (ALHC) | United States | $3.041B | 0.00 |
| Surgery Partners (SGRY) | United States | $3.026B | 39.35 |
| Concentras Parent (CON) | United States | $2.772B | 16.02 |
| Organon (OGN) | United States | $2.397B | 2.55 |
| Ardent Health Partners (ARDT) | United States | $2.071B | 8.83 |
| GeneDx Holdings (WGS) | United States | $2.032B | 78.26 |
| Premier (PINC) | United States | $1.892B | 14.36 |
| Progyny (PGNY) | United States | $1.843B | 40.57 |
| PACS (PACS) | United States | $1.512B | 0.00 |
| GoodRx Holdings (GDRX) | United States | $1.400B | 28.00 |
| Pediatrix Medical (MD) | United States | $1.216B | 9.25 |
| Teladoc Health (TDOC) | United States | $1.214B | 0.00 |
| Ryman Healthcare (RYHTY) | New Zealand | $1.011B | 0.00 |
| Establishment Labs Holdings (ESTA) | $0.995B | 0.00 | |
| CareDx (CDNA) | United States | $0.946B | 14.77 |
| Nutex Health (NUTX) | United States | $0.934B | 14.11 |
| Agilon Health (AGL) | United States | $0.919B | 0.00 |
| QDM (QDMI) | Hong Kong, SAR China | $0.848B | 0.00 |
| AMN Healthcare Services Inc (AMN) | United States | $0.808B | 7.57 |
| Embecta (EMBC) | United States | $0.615B | 4.15 |
| LifeMD (LFMD) | United States | $0.555B | 0.00 |
| InnovAge Holding (INNV) | United States | $0.552B | 0.00 |
| Enhabit (EHAB) | United States | $0.532B | 43.75 |
| SBC Medicals (SBC) | United States | $0.532B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.474B | 10.67 |
| Sonida Senior Living (SNDA) | United States | $0.460B | 0.00 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.389B | 0.00 |
| Oncology Institute (TOI) | United States | $0.285B | 0.00 |
| Performant Healthcare (PHLT) | United States | $0.240B | 0.00 |
| Beauty Health (SKIN) | United States | $0.205B | 0.00 |
| KindlyMD (KDLY) | United States | $0.150B | 0.00 |
| DocGo (DCGO) | United States | $0.145B | 23.67 |
| KindlyMD (NAKA) | United States | $0.136B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.112B | 0.00 |
| OncoCyte (OCX) | United States | $0.095B | 0.00 |
| So-Young (SY) | China | $0.087B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.067B | 0.00 |
| NeueHealth (NEUE) | United States | $0.061B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.059B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.058B | 0.00 |
| Biodesix (BDSX) | United States | $0.044B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.041B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.030B | 0.00 |
| ModivCare (MODV) | United States | $0.016B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.012B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.010B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.009B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.008B | 0.00 | |
| XWELL (XWEL) | United States | $0.005B | 0.00 |
| Aclarion (ACON) | United States | $0.004B | 0.00 |
| INVO Fertility (IVF) | United States | $0.004B | 0.00 |
| ISpecimen (ISPC) | United States | $0.003B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.001B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |